Thawed solvent/detergent-treated plasma demonstrates comparable clinical efficacy to thawed plasma.

TitleThawed solvent/detergent-treated plasma demonstrates comparable clinical efficacy to thawed plasma.
Publication TypeJournal Article
Year of Publication2020
AuthorsRacine-Brzostek SE, Canver MC, DeSimone RA, Zdravkova M, Lo DT, Crowley KM, Hsu Y-MS, Vasovic LV, Hill SSykes, Cushing MM
JournalTransfusion
Volume60
Issue9
Pagination1940-1949
Date Published2020 09
ISSN1537-2995
KeywordsAdolescent, Adult, Aged, Aged, 80 and over, Blood Coagulation Disorders, Blood Component Transfusion, Blood Preservation, Detergents, Female, Humans, Male, Middle Aged, Partial Thromboplastin Time, Pilot Projects, Plasma, Retrospective Studies, Solvents, Transfusion Reaction
Abstract

BACKGROUND: Thawed Plasma (TP), plasma thawed and refrigerated for up to 5 days, is a commonly transfused plasma product. This pilot study was conducted to determine whether Thawed Solvent/Detergent-treated Plasma stored refrigerated for up to 5-days post-thaw (T-S/D) was as efficacious as TP.

STUDY DESIGN AND METHODS: This single institution retrospective cohort analysis evaluated the efficacy of T-S/D in reversing coagulopathies in comparison to TP. Utilizing the institution's electronic medical records, transfusion data were collected in adult patients who received either TP or T-S/D. The primary outcome was the incidence of subsequent transfusions within 24 hours after first dose of either type of plasma. Secondary outcomes included the number of blood products transfused within 24 hours of first-dose plasma, correction of pre-transfusion coagulation laboratory values, volume transfused, and clinical outcomes.

RESULTS: TP was received by 301 patients and 137 received T-S/D during the first 32 months post-implementation of T-S/D. There was no difference in incidence of subsequent transfusions or number of blood products given. The median pre-INR of both the TP and T-S/D cohorts was 1.9, with a similar decrease in INR of 0.2 and 0.3 (p = 0.36), respectively, post plasma transfusion. There was no difference in correction of PT/aPTT, mortality, transfusion reactions, readmission rates, length of stay, or inpatient deep venous thrombosis. The median volume of T-S/D plasma transfused for the first dose was 126 mL less than TP (p = .0001).

CONCLUSION: T-S/D was as efficacious as TP for the treatment of coagulopathies and the reversal of coagulation laboratory values.

DOI10.1111/trf.15948
Alternate JournalTransfusion
PubMed ID32720432
Related Faculty: 
Melissa Cushing, M.D. Robert DeSimone, M.D. Sabrina Racine-Brzostek, M.D., Ph.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700